ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 663

Propylthiouracil Attenuates Aortic Vasculopathy In An Animal Model Of Systemic Sclerosis

Gianluca Bagnato1, Alessandra Bitto2, Gabriele Pizzino2, Neal Roberts3, Domenica Altavilla2, Francesco Squadrito2, Gianfilippo Bagnato1 and Antonino Saitta4, 1Rheumatology, University of Messina, Messina, Italy, 2Pharmacology, University of Messina, Messina, Italy, 3University of Louisville, Louisville, KY, 4Internal Medicine, University of Messina, Messina, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, systemic sclerosis and thyroid

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic sclerosis (SSc) is a generalized connective tissue disorder of unknown etiology characterized by thickening and fibrosis of the skin and distinctive visceral involvement associated with vascular damage. Traditionally, the vasculopathy of SSc has been considered mainly to affect small arteries and capillaries but there is recent evidence showing that SSc is also associated with large vessel disease. Increased aortic augmentation index and pulse wave velocity in comparison to age and sex matched healthy controls indicate large-vessel involvement in patients with SSc. A second , and as yet poorly accounted for, endocrine feature of scleroderma is its overlap with thyroid abnormalities. Recent experimental data suggest that propylthiouracil (PTU) abrogates the development of cutaneous and pulmonary fibrosis in SSc murine model and reduces the development of plexiform lesions in an animal model of primary pulmonary hypertension. The aim of the study is therefore to evaluate the effect of propylthiouracil administration on intima-media (IM) thickness and ratio in a murine model of systemic sclerosis. 

Methods: Chronic oxidant stress SSc was induced in BALB/c mice by daily subcutaneous injections of HOCl for 6 weeks, characterized in detail as the Cochin chronic oxidant stress model of SSc . Mice (n=25) were randomized in three arms: treatment with either propylthiouracil plus HOCl (n=10), HOCl (n=10), or vehicle alone (n=5). Propylthiouracil treatment (12 mg/kg) was initiated 30 minutes after HOCl subcutaneous injection and continued daily for the 6 weeks. Thoracic aorta was evaluated by histological methods. IM thickness and ratio were measured for statistical analysis.

Results: HOCl injections induced an increase in aortic IM thickness when compared to controls by 101% (p<0.0001). In mice treated with HOCl and PTU there was a 86% reduction of IM thickness (p<0.0001). PTU treated animals had a significantly thinner intima layer (-13%, p<0.0001) and media layer (-198%, p<0.0001) compared to HOCl group. IM ratio was also decreased in HOCl treated mice compared to controls (0.72 vs 1.76, p<0.0001)  and significantly increased by PTU administration (1.62 vs 0.72, p<0.0001).

Conclusion: Our data suggest that PTU, probably through its antioxidant direct effect or indirectly through thyroid function inhibition , substantially moderates the increase of aortic thickness found in HOCl treated animals reducing collagen deposition in media layer and aortic fibrotic changes.


Disclosure:

G. Bagnato,
None;

A. Bitto,
None;

G. Pizzino,
None;

N. Roberts,
None;

D. Altavilla,
None;

F. Squadrito,
None;

G. Bagnato,
None;

A. Saitta,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/propylthiouracil-attenuates-aortic-vasculopathy-in-an-animal-model-of-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology